Richard Burack

7.1k total citations · 1 hit paper
114 papers, 4.8k citations indexed

About

Richard Burack is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Richard Burack has authored 114 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pathology and Forensic Medicine, 36 papers in Molecular Biology and 30 papers in Oncology. Recurrent topics in Richard Burack's work include Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Viral-associated cancers and disorders (15 papers). Richard Burack is often cited by papers focused on Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Viral-associated cancers and disorders (15 papers). Richard Burack collaborates with scholars based in United States, Netherlands and Canada. Richard Burack's co-authors include Andréy S. Shaw, Paul M. Allen, Michael L. Dustin, Rodney L. Biltonen, Tasha N. Sims, Kyeong‐Hee Lee, Cenk Sumen, Jonathan W. Friedberg, Kenneth G. Johnson and Mark M. Davis and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Biological Chemistry.

In The Last Decade

Richard Burack

108 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Immunological Synapse

2001 773 citations Richard Burack, Andréy S. Shaw et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Burack United States	33	1.9k	1.8k	1.1k	867	509	114	4.8k
Vladimir Lazar France	46	4.1k 2.2×	974 0.6×	2.1k 2.0×	607 0.7×	441 0.9×	133	7.4k
Donald L. Durden United States	38	3.3k 1.8×	997 0.6×	1.1k 1.0×	327 0.4×	364 0.7×	108	5.3k
Bharat Joshi United States	42	2.8k 1.5×	1.6k 0.9×	1.1k 1.0×	165 0.2×	847 1.7×	109	5.5k
Johan Botling Sweden	39	2.8k 1.5×	1.1k 0.6×	1.6k 1.5×	558 0.6×	257 0.5×	117	5.3k
Wendy J. Fantl United States	38	4.7k 2.5×	1.8k 1.0×	1.1k 1.0×	427 0.5×	666 1.3×	68	7.2k
Yohei Miyagi Japan	47	3.4k 1.8×	1.1k 0.6×	2.3k 2.2×	421 0.5×	554 1.1×	324	8.2k
Ole Didrik Lærum Norway	42	2.0k 1.1×	643 0.4×	1.3k 1.2×	267 0.3×	591 1.2×	200	5.3k
Jacques Colinge Austria	37	4.4k 2.4×	1.8k 1.0×	1.1k 1.0×	255 0.3×	433 0.9×	103	7.3k
Roberto Chiarle Italy	47	4.5k 2.4×	1.5k 0.9×	2.9k 2.7×	1.8k 2.1×	366 0.7×	149	7.9k
I. Kozieradzki Canada	27	3.2k 1.7×	2.6k 1.5×	1.5k 1.4×	190 0.2×	511 1.0×	38	6.9k

Countries citing papers authored by Richard Burack

Since Specialization

Citations

This map shows the geographic impact of Richard Burack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Burack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Burack more than expected).

Fields of papers citing papers by Richard Burack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Burack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Burack. The network helps show where Richard Burack may publish in the future.

Co-authorship network of co-authors of Richard Burack

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Burack. A scholar is included among the top collaborators of Richard Burack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Burack. Richard Burack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

George, Giby V., Małgorzata Kajstura, Audrey N. Jajosky, et al.. (2025). Association Between B-Cell Marker Expression and RUNX1 Lesions in Acute Myeloid Leukemia, Beyond RUNX1::RUNX1T1 Fusion: Diagnostic Pitfalls with Mixed-Phenotype Acute Leukemia—B/Myeloid. Cancers. 17(8). 1354–1354. 1 indexed citations

Chaves, Francisco A., Yi Zhang, Richard Burack, et al.. (2025). Apolipoproteins from the microenvironment promote aggressive myeloid leukemia progression. Blood. 146(Supplement 1). 3186–3186.

Burack, Richard, Hongli Li, Diana G. Adlowitz, et al.. (2023). Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma. Blood Advances. 7(17). 5082–5090. 6 indexed citations

Hussein, Siba El, Hong Fang, Fatima Zahra Jelloul, et al.. (2023). T-Cell–Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Archives of Pathology & Laboratory Medicine. 148(8). 914–920. 1 indexed citations

Palacios, Florencia, Xiao‐Jie Yan, Gerardo Ferrer, et al.. (2021). Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia. 35(4). 1037–1052. 18 indexed citations

Burack, Richard, et al.. (2018). A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia. Leukemia Research. 75. 15–22. 5 indexed citations

Hunter, Bradley D., Megan M. Herr, Ferdous M. Barlaskar, et al.. (2016). Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma & Leukemia. 17(3). 145–151. 9 indexed citations

Cook, Erika M., Margaret A. Lindorfer, Simone C. Oostindie, et al.. (2016). Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. The Journal of Immunology. 197(5). 1762–1775. 48 indexed citations

Rosenberg, Alexander F., Shannon P. Hilchey, Ollivier Hyrien, et al.. (2016). Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node. PLoS ONE. 11(5). e0155347–e0155347. 20 indexed citations

10.

Frederiksen, John K., Meenal Sharma, Carla Casulo, & Richard Burack. (2015). Systematic Review of the Effectiveness of Fine-Needle Aspiration and/or Core Needle Biopsy for Subclassifying Lymphoma. Archives of Pathology & Laboratory Medicine. 139(2). 245–251. 93 indexed citations

11.

Lindorfer, Margaret A., Erika M. Cook, Clive S. Zent, et al.. (2015). Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Molecular Immunology. 70. 13–23. 23 indexed citations

12.

Spence, John C. H., et al.. (2014). Intraclonal Diversity in Follicular Lymphoma Analyzed by Quantitative Ultradeep Sequencing of Noncoding Regions. The Journal of Immunology. 193(10). 4888–4894. 8 indexed citations

13.

Burack, Richard, et al.. (2014). Immunohistochemical Expression of mTOR in Germinal Center and Nongerminal Center Group of Diffuse Large B-Cell Lymphoma: A Clinicopathological Study. Clinical Lymphoma Myeloma & Leukemia. 15(3). 159–163. 1 indexed citations

14.

Friedberg, Jonathan W., Daruka Mahadevan, Daniel O. Persky, et al.. (2013). Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 32(1). 44–50. 161 indexed citations

15.

Friedberg, Jonathan W., Joseph M. Unger, Richard Burack, et al.. (2010). R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433. Blood. 116(21). 590–590. 6 indexed citations

16.

Halldórsdóttir, Anna Margrét, Barbara A. Zehnbauer, & Richard Burack. (2007). Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular lymphoma specimens: Superior performance of the IGK assays compared to IGH for suboptimal specimens. Leukemia & lymphoma. 48(7). 1338–1343. 31 indexed citations

17.

Markiewicz, Mary A., Leonidas N. Carayannopoulos, Olga V. Naidenko, et al.. (2005). Costimulation through NKG2D Enhances Murine CD8+ CTL Function: Similarities and Differences between NKG2D and CD28 Costimulation. The Journal of Immunology. 175(5). 2825–2833. 101 indexed citations

18.

Burack, Richard, Kyeong‐Hee Lee, Amy D. Holdorf, Michael L. Dustin, & Andréy S. Shaw. (2002). Cutting Edge: Quantitative Imaging of Raft Accumulation in the Immunological Synapse. The Journal of Immunology. 169(6). 2837–2841. 117 indexed citations

19.

Burack, Richard, et al.. (1992). Expression of a group II phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus in Escherichia coli: Recovery and renaturation from bacterial inclusion bodies. Protein Expression and Purification. 3(6). 512–517. 27 indexed citations

20.

Burack, Richard & Paul R. Draskóczy. (1962). THE MODE OF SECRETION OF CATECHOLAMINES FROM THE ADRENAL MEDULLA. Journal of Pharmacology and Experimental Therapeutics. 138(2). 165–169. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact